An observational study in Coronary Artery Disease, sponsored by Scitech Produtos Medicos Ltda. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-04.
Sponsored by Scitech Produtos Medicos Ltda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 30 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 8th largest by enrollment of the 28 observational ones that give a count, is one of 11 that started in 2017, is one of 29 observational ones, and was the 88th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:
Scitech Produtos Medicos SA · Sites in Brazil
Ages 18+
InCor Heart Institute · Sites in Brazil
Ages 45–70 · Women only
University of Sao Paulo General Hospital · Sites in Brazil
Ages 46–69 · Men only
Instituto Nacional de Cardiologia de Laranjeiras · Sites in Brazil
Ages 40–70 · Healthy volunteers
University of Sao Paulo General Hospital · Sites in Brazil
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 25 · Phase 4 17
First in 1999; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,504 is above the median of 326 across 1,689 observational studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 123 interventional studies, 740 across the 28 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 152 have an industry lead sponsor. The 10 most frequent:
Scitech Produtos Medicos Ltda is the lead sponsor of 13 studies on the registry; none are open to participants now.
Scitech Produtos Medicos Ltda has 9 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Coronary Artery Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06579807Instituto Nacional de Cardiologia de LaranjeirasCardiac Rehabilitation and Coronary Artery Disease | 2026-12-31 |
| NCT07699679Federal University of São PauloPhotobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting. | 2027-08 |
| NCT07734831University of the State of Santa CatarinaTELEREHAB-BR: Cardiovascular Rehabilitation Models Trial | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 152 studies in Coronary Artery Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.
Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0 mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent.
Stent implantation should be performed according to the Instructions for Use and according to the local practice. It is recommended that ECG and cardiac enzymes are collected before and after procedure. Dual anti-platelet therapy is recommended for at least 6 months after procedure.
Patients will be followed at 30 days, 1 and 2 years after procedure.
Patients older than 18 years submitted to implant of the Inspiron Sirolimus Eluting Stent in native coronary arteries
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
Device: implant
coronary stent implantation
Major Adverse Cardiac Events Rate
Cardiac Death, MI, Target Lesion Revascularization and Stent Thrombosis
Time frame: 12 months
Target Vessel and Lesion Revascularization Rates
Target Vessel and Lesion Revascularization
Time frame: 24 months
Stent Thrombosis Rate
Stent Thrombosis
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in Dec 2022, 66 months.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 66 months is above that.
Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Scitech Produtos Medicos Ltda